Design, Development and optimization of chronomodulatedPulsincap delivery system of Valsartan by Abhimanyu et al.
 
Asian Pac. J. Health Sci., 2019; 6(1):10-21                                                  e-ISSN: 2349-0659, p-ISSN: 2350-0964 
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Abhimanyu et al                     ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2019;6(1):10-21                                  10 
www.apjhs.com       
 
 
Document heading doi: 10.21276/apjhs.2019.6.1.2                                                                                              Research Article   
Design, Development and optimization of chronomodulatedPulsincap delivery system of 
Valsartan 
Abhimanyu1, Anurag Bhargava1, Prabhjot Singh Bajwa1, Binu Raina1, Pankaj sharma2, Shailesh Sharma3 
 
1 Ch. Devi Lal College of Pharmacy, Jagadhri, Yamuna Nagar, Haryana, India 
2 School of Pharmaceutical Sciences, Jaipur National University, Jaipur, Rajasthan, India 
3Department of Pharmaceutics, Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, 
Bela, Punjab, India 
 
Received: 10-02-2018 / Revised: 29-06-2018 / Accepted: 13-06-2018 
 
Abstract 
 
Aim of the present study was to formulate, evaluate and optimize the Pulsincap delivery system of valsartan used for 
treatment of hypertension, based on the chronotherapeutic approach. The prepared pulsincap system consist of 
immediate release tablet sealed inside formaldehyde treated insoluble capsule body by hydrogel plug composed of 
polymer HPMC K15M and guar gum. The formulation produced was targeted for the preparation of time controlling 
pulsatile formulation to delivery drug to site and time controlling for enhancing the bioavailability of drug, so 
preliminary batches were prepared to study the effect of concentration of HPMC K15M and guar gum on the lag 
time of the drug release. Optimization of hydrogel plug was carried out by employing 32 full factorial design using 
Design expert 7 Software.  
 
Keywords: Chronothepary, Valsartan,hypertension , Pulsatile capsule, 32 Full factorial design.  
Introduction 
 
Pulsatile Drug Delivery System (PDDS) is a time- 
specific and site-specific drug delivery system, thereby 
it provides special and temporal delivery and increase 
patient compliance also. This system can be of great 
use for the drugs which do not require a constant drug 
release i.e. do not desire a Zero- order release.   
PDDS can be defined as the rapid and transient release 
of certain number of molecules within a short–time 
immediately after a pre–determined off-release period, 
i.e. lag time. Lag time is defined as the time between 
the placement of dosage form into an aqueous 
environment and the time at which the active 
ingredient begins to get released from the dosage from. 
[1]  
‘Chrono pharmaceutics’ is a word made after 
compiling two words, Chronobiology and 
Pharmaceutics. 
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Chronobiology is the study of biological rhythms and 
their mechanisms. There are 3 types of mechanical 
rhythms in our body:  
• Circadian: This word comes from Latin word 
‘circa’ means about and ‘dies’ means day.  
• Ultradian: Oscillations of shorter duration are 
termed as ultradian (more than 1 cycle 24 hrs) [4] 
• Infradian: Oscillations that are longer than 24 hrs 
(less than one cycle per day) [2] 
It is well- documented that majority of the body 
functions exhibit circadian rhythms e.g. heart rate, 
stroke volume, blood pressure, blood flow, body 
temperature, gastric pH etc. Moreover, in several 
organs their functions vary with the time of the day. 
[3]Cardiovascular disorders such as angina, heart 
attack, hypertension, stroke and sudden cardiac death. 
The differences in patterns of illness between day and 
night for these disorders have been documented. 
Dosing schedules have been made, medications have 
been formulated to provide appropriate concentration 
of a drug in body where drug is most needed. For 
example – blood pressure of a hypertensive patient 
increases rapidly after awakening and it peaks in the 
middle to late time of the day, decreases in the evening 
and it is lowest while the patient sleep at night [5]. 
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In the present study, Valsartan was selected as the 
model drug. Valsartan blocks the actions of angiotensin 
II, which include constricting blood vessels and 
activating aldosterone, to reduce blood pressure. The 
drug binds to angiotensin type I receptors (AT1), 
working as an antagonist. This mechanism of action is 
different than the ACE inhibitor drugs, which block the 
conversion of angiotensin I to angiotensin II. Since 
valsartan acts at the receptor, it can provide more 
complete angiotensin II antagonism since angiotensin 
II is generated by other enzymes as well as ACE. Also, 
valsartan does not affect the metabolism of bradykinin 
like ACE inhibitors do. In order to obtain an 
appropriate formulation with minimum experiments, 
optimization method was adopted in the present study. 
A 32 full factorial design was chosen to optimize the 
variables. The search for the optimum was carried out 
using desirability function as this technique involves 
a way of overcoming difficulty of multiple, sometimes 
opposing responses. 
MATERIALS AND METHOD 
Materials 
Valsartan, hydroxyl propyl methyl cellulose (HPMC 
K15M) and Avicel pH101 was obtained fromZydus 
Cadilla, Ahmedabad.Guar gum, sodium starch 
glycolate, talc and magnesium stearate were obtained 
from Nice Chemicals Pvt. Ltd. Kerala, IndiaEthyl 
cellulose and ac-di-sol was obtained from Optica 
Pharmaceuticals, Haryana, India.Ethanol was obtained 
from modi mill, Yamuna nagar, Haryana. 
Drug-Excepient compatibility study by FTIR 
The FTIR absorption spectra was performed for 
various physical mixtures of polymer and drug. The 
physical mixtures were then scanned at wavelength 
4000 cm-1- 400 cm-1. The spectra were then studied for 
peaks obtained by comparing with the spectra of pure 
drug as seen in figure 1 and figure 2. 
                 Preparation of cross-linked gelatine capsules 
(Capsule no 1 plug 6 mm bound by EC mixture) 
Formaldehyde treatment 
Formalin treatment has been employed to modify the 
solubility of gelatine capsules.  Exposure to formalin 
vapours results in an unpredictable decrease in 
solubility of gelatine owing to the cross linkage of the 
amino group in the gelatine molecular chain aldehyde 
group of formaldehyde by Schiff’s base 
condensation.Fifty millilitres of 10% (v/v) 
formaldehyde was taken into desiccator and a pinch of 
potassium permanganate was added to it, to generate 
formalin vapours. The wire mesh containing the empty 
bodies of the 100 mg capacity hard gelatine (about 100 
in number) capsule was then exposed to formaldehyde 
vapours. The caps were not exposed leaving them 
water-soluble. The desiccator was tightly closed. The 
reaction was carried out for 12 hrs after which the 
bodies were removed and dried at 50 °C for 30 min to 
ensure completion of reaction between gelatine and 
formaldehyde vapours.  The bodies were then dried at 
room temperature to facilitate removal of residual 
formaldehyde. These capsule bodies were capped with 
untreated caps and stored in a polythene bag. [6,7] 
Test for formaldehyde treated empty capsule bodies 
Various physical tests, such as identification 
attributes, visual defects, changes in dimension  were 
carried out. 
Solubility studies for the treated capsules 
When the capsules were subjected to solubility studies 
in different buffers for 24 hrs, the following 
observation were made a) In all the case of normal 
capsules, both cap and body dissolved within fifteen 
minutes.  b) In the case of formaldehyde treated 
capsules, only the cap dissolved within 15 min, while 
the capsule remained intact for about 24 hrs.   
Quantity test for free formaldehyde  
The formaldehyde capsules were tested for the 
presence of free formaldehyde. Limit test for the 
presence of residual formaldehyde was carried. The 
sample solution was less intensively coloured when 
compared with standard inferring that less than 20 
μg/ml of free formaldehyde is present in 25 capsules 
bodies) as per the I.P.[8] 
Preparation of immediate release tablets 
Immediate release coretablets were prepared by direct 
compression of a homogenous mixture of valsartan, 
Avicel PH-101, Ac-di-sol, Sodium starch glycolate, 
magnesium stearate & talc as given in Table 1. Weight 
variation, Hardness and Disintegration time were 
measured for the core tablets. Press coated tablets were 
formulated using different polymers as outer coating 
for core tablet including Ethyl Cellulose,HPMC K100, 
Guar Gum and Avicel. 
Evaluation of immediate release tablets 
The thickness and diameter of the tablets (n=10) were 
determined using micrometer [9]. The hardness of the 
tablets (n=10) was determined by using the pfizer 
hardness tester [10]Electrolab, Mumbai, India. The 
friability (%) of the tablets was determined by 
takingSample of whole tablets corresponding to about 
6.5gm placed in the friabilator and were subjected to 
100 revolutions [11]. The tablets were taken out, de 
dusted and reweighed to determine the friability of all 
the batches. Weight variation test of the tablets (n=20) 
was carried out as per the official method [12]. The 
disintegration time of core tablets was determined by 
the Disintegration tester USP [13] (ED-2AL, 
Electrolab, Mumbai, India). The drug content and 
uniformity of valsartan was determined using UV 
Spectrophotometer. The contents of 1 capsule transfer 
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to a 100 ml volumetric flask and dissolved in a suitable 
quantity of distilled water and sonicated for about 15 
minutes. This solution adjusted with water to volume in 
100 ml volumetric flask. The solution was used as 
stock solution and filtered using filter paper. Ten ml of 
sample was withdrawn from this solution and dilute up 
to 100 ml distilled water in 100 ml volumetric flask. 
The amount of drug was determined using UV 
spectrophotometer at 248 nm. The content of each 
batch was determined in replicates of three. [14] 
 Preparation of hydrogel plug 
Hydrogel plugs (preliminary batches) were prepared by 
varying the concentration of polymer HPMC K15M 
and guar gum by direct compression technique using 
single punch tablet machine according to the formula 
mentioned in table 2. The average weight of hydrogel 
plug was found to be 100mg.  
Evaluation of hydrogel plug 
Hydrogel plug containing HPMC and guar gum were 
evaluated for weight variation, thickness and hardness. 
Development of pulsincap system 
One tablet from the optimized batch of core tablets was 
placed into the previously formaldehyde treated bodies 
by hand filling. The bodies containing the core tablet, 
were then plugged with hydrogel plug as shown in 
Table 4.8. Then the capsule body and cap were joined 
and sealed with a small amount of 5% ethyl cellulose 
ethanolic solution.   
In vitro dissolution study of the capsule 
The dissolution testing of pulsed capsule was carried 
out using a USP Type II dissolution apparatus at 
37±0.5 °C in 900 ml phosphate buffer pH 6.8 and a 
paddle speed of 75 rev./min. The in vitro dissolution 
study of pulsatile capsule device was carried out using 
USP Type II dissolution apparatus. The capsules were 
tied to circular wire mesh of diameter 2 cm and 
immersed in the dissolution medium. The study was 
carried out in 900 ml of 0.1 N HCl for the first 2 h, 
followed by 900 ml of phosphate buffer (pH 6.8). The 
dissolution medium was maintained at 37±0.5 °C. The 
paddle was lowered so that the lower end of the stirrer 
was 25mm above from the base of the beaker. The 
capsule assembly was tied to a wire mesh that was then 
introduced into the dissolution vessel and the paddle 
was rotated at 75 rpm. At different time intervals, 5 ml 
of sample was withdrawn and analyzed by UV–Visible 
spectrophotometer at 248 nm. At each time of 
withdrawal, 5 ml of fresh corresponding medium was 
replaced into the dissolution vessel. [15] 
Experimental design 
A two factor, three level (32) FFD was used in the 
optimization of Hydrogel plug. The study design 
involved the investigation of the effect of independent 
variables viz concentration of HPMC (X1) and 
concentration of guar gum (X2) on the dependent 
variable lag time.  
The levels of the factors studied were chosen based on 
results of preliminary studies, so that their relative 
difference was adequate to have a measurable effect on 
the response, along with the information that the 
selected levels are within practical use. After 
developing the experimental design nine batches of 
hydrogel plug were formulated. Nine formulations 
(Table 3) were prepared according to the experimental 
design. 
The factorial design is a simplified representation in 
analytical form of a given reality. In this mathematical 
approach, each experimental response Y can be 
represented by a quadratic equation of the response 
surface: Y = β0 + β1 X1 + β2 X2+ β3 X1 X2 + β4 X12 + β5 
X22, in which Y is the measured response associated 
with each factor-level combination; X1 and X2 are the 
factors studied; B0 is an intercept; B1– B5 are the 
regression coefficients. The equation enabled the 
study of the effects of each factor and their interaction 
over the considered responses. 
Optimization of hydrogel plug 
The optimization process was used to obtain a model 
equation that provides a means of evaluating changes 
in response due to changes in the independent variable 
levels. After application of full factorial design and 
with help of polynomial terms the optimized pulsincap 
system (PCZ1) was produced. Pulsincap formulation 
was prepared as per the composition given in Table4. 
This batch targeted to lag time 360 min.  
Stability studies 
In order to assess stability, the optimum pulsincap of 
Valsartan were packed in an amber colored air tight 
vial and stored at (40 ± 2 °C and 75 ± 5% RH) for a 
period of 6 months. The formulations were withdrawn 
after a period, analyzed for physical appearance, 
weight, drug content, and lag time. At this point, the 
data was statistically analyzed using ANOVA to test 
the significance of difference at the level of 
significance 0.05. 
RESULTS AND DISCUSSION 
Preformulation studies 
Drug and excipient studies were performed and FTIR 
studies revealed that there is no 
incompatibility between drug and excipients used in 
the study. The IR spectrum of valsartan exhibits 
characteristic peaks at 3304 cm1 (N–H functional 
group), 2960 cm1 (C–H group stretching vibration), 
1728 cm1 (carboxyl carbonyl), 1598 cm1 (amide 
carbonyl group). The peak at 1467 cm1 indicates the 
presence of CQC aromatic group. Appearance of these 
peaks in the physical mixture and liquisolid 
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formulation indicate the absence of chemical 
interaction between the drug and excipients. 
Physical test 
It was found that after formaldehyde treatmentthe 
length and dimension of capsule bodies were decreased 
Disintegration test of capsules 
It was found that the untreated capsules and the caps of 
treated capsules were disintegrated within 20 min. 
whereas the treated capsules remained intact for 24 
hours 
Formaldehyde treatment of empty gelatin capsule 
Formalin treatment has been employed to modify the 
solubility of the gelatin capsules. Exposure to 
formalin vapors results in an unpredictable decrease in 
solubility of gelatin owing to the cross-linkage of the 
amino groups in the gelatin molecular chain with 
aldehyde groups of formaldehyde by Schiff’s base 
condensation. The solubility tests were carried out for 
untreated capsules and formaldehyde treated capsules 
for 24 h. It was observed that in all untreated capsules, 
both cap and body dissolved within 30 min, whereas in 
formaldehyde-treated capsules, only the cap dissolved 
within 30 min, while the capsule body remained intact 
for about 24 h and hence indicates the suitability for 
colon targeting. The formaldehyde capsules were tested 
for the presence of free formaldehyde. The sample 
solution was not more intensely colored than the 
standard solution, inferring that less than 0.8 mg of free 
formaldehyde per capsule was present as 
residual amount. 
Evaluation of prepared powder blend  
Prepared powder blend of immediate release core tablet 
and hydrogel plug was subjected to evaluate various 
micromeritic properties. It was found that the powder 
exhibit good flow property as evident from the table 5 
and 6 
Evaluation of prepared immediate release tablet 
Prepared immediate release tablets were subjected to 
check various physico-chemical properties and the 
values were found within the limits. Results are 
depicted in table 7 
Evaluation of compressed hydrogel plug and 
pulsincap system 
After formulating preliminary batches of hydrogel 
plugs, the evaluation study of hydrogel plugs was 
carried out, and the results obtained are represented in 
Table 8. It was found that all the formulations 
exhibited uniform weight with low standard deviation 
values, indicating the uniformity of the weight in 
hydrogel plugs prepared by direct compression method. 
The weight of the hydrogel plug varied between 101.73 
mg and 98.42 mg. Range of hydrogel plug thickness 
was found to be between 6.245mm – 6.52mm.Hardness 
of hydrogel plug was determined by Pfizer hardness 
tester taking average of ten hydrogel plugs. It was 
found that with the increase in concentration of 
polymer there was an increase in the hardness value of 
plug. Range of hardness for hydrogel plug was in 
between 2.47 kg/cm2 – 4.37 kg/cm2 with minimum 
standard deviation. 
In vitro dissolution studies 
In vitro drug release from pulsincap delivery system 
containing hydrogel plug with varying polymer 
concentration is depicted fig 3. each formulation 
released the drug after a certain lag time and the lag 
time attained was dependant on type and concentration 
of polymer. It was found that maximium lag time (440 
min) was shown by the formulation PP1containing 
45mg of HPMC k15and minimum lag time (300 min) 
was shown by formulation PP4 containing 35mg of 
HPMC k15. Based onpreliminary studies, it was found 
that with increase in the concentration of the polymer 
the lag time of drug release was also increased. Based 
on values of hardness obtained it was observed that 
with decreasing the concentration of polymer value of 
hardness also decreased. Based on these findings 
combination of polymer was selected for further 
studies. 
Statistical and response surface analysis of models 
for lag time  
Statistical analysis 
It was investigated, lag time showed a wide variation 
with change in concentration of two factors. Table 9 
describes effect of HPMC and guar gum. It was found 
that with increase in concentration of HPMC and guar 
gum lag time for drug release also increased. 
According to dissolution profile it was found that lag 
time PP1-PP9 (fig. 4) varied between 300-440 min. 
Formulation PP2 released drug after a lag time of 370 
min. and the percentage of drug released from the 
formulation was found to be 97.98%. 
Optimization  
Optimization was done employing a 32 FFD. The 
dependent and independent variables were related 
using quadratic equations obtained with the Design 
Expert software (Design Expert 7) ANOVA was 
performed to identify insignificant factors. Model 
selection was based on lower p values than assigned 
significance level, high F value i.e.65.72, absence of 
lack of fit, highest level of adjusted R2 and predicted 
R2, low standard deviation and lower PRESS value. All 
values are represented in Table 10. All values 
implythat the model is significant. High value of R2 for 
dependent variable was obtained, which indicate a 
good fit. Value of p less than 0.05 indicated that model 
terms are significant. 
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Response surface analysis 
Response surface plot was generated for response to 
study the behavior of the system. Response surface 
plot for hardness in fig.5 and fig.6 shows that with the 
increase in the concentration of HPMC lag time of drug 
increases in linear manner and with increase in 
concentration in guar gum the lag time value of 
the hydrogel plug also increases in a curvilinear 
manner. 
Table 1: Composition obtained for optimized batch 
 
Ingredients Fast release core tablet 
Valsartan 80 
Acdisol 4.32 
Sodium starch glycolate 4.36 
Avicel PH 101 67.32 
Magnesium Stearate 2 
Talc 2 
 
Table 2:Formulation of trial batch of Pulsed capsule 
 
Batch PG1 PG2 PG3 PG4 PG5 PG6 PG7 PG8 PG9 
HPMC K15M 30 40 50 0 0 0 30 40 50 
Guar Gum 0 0 0 20 30 40 40 30 20 
Avicel pH101 66 56 46 76 66 56 26 26 26 
Mg Stearate 2 2 2 2 2 2 2 2 2 
talc 2 2 2 2 2 2 2 2 2 
 
 
Table 3:Formulation of the Pulsed capsule with Immediate release core tablet 
 
Formulation code 
Immediate release 
tablet (mg) 
Hydrogel composition (mg) 
HPMC K15M Guar gum Avicel pH101 Magnesium stearate 
PP1 150 45 30 24 1 
PP2 150 40 25 34 1 
PP3 150 45 25 29 1 
PP4 150 35 25 39 1 
PP5 150 35 30 34 1 
PP6 150 45 35 19 1 
PP7 150 40 35 24 1 
PP8 150 35 35 29 1 
PP9 150 40 30 29 1 
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Table 4: Composition obtained for optimized batch of Pulsed Capsule 
 
Ingredients Pulsed Capsule (PCZ1) 
Core Tablet 150 
HPMC K15m 38.3 
Guar Gum 29.85 
Avicelph 101 27.85 
Mg stearate 2 
Talc 2 
 
Table 5: Characterization of powder blends of core tablets 
Parameters 
Bulk density 
(gm/cm3) 
Tapped density 
(gm/cm3) 
Compressibility 
index (%) 
Hausner’s 
Ratio 
Angle of 
repose (º) 
CT1 0.365± 0.016 0.406± 0.022 10.056± 1.062 1.112± 0.013 27.683± 0.229 
CT2 0.377± 0.019 0.421± 0.018 10.618± 0.623 1.119± 0.008 28.33± 0.46 
CT3 0.364± 0.019 0.409± 0.019 11.018± 0.709 1.124± 0.009 28.018± 0.346 
CT4 0.367± 0.009 0.413± 0.011 11.122± 0.632 1.125± 0.008 28.798± 1.014 
CT5 0.39± 0.008 0.436± 0.013 10.541± 0.902 1.118± 0.011 27.256± 0.885 
CT6 0.382± 0.016 0.424± 0.019 9.743± 1.07 1.108± 0.013 27.822± 0.528 
CT7 0.361± 0.021 0.399± 0.022 9.617± 1.187 1.107± 0.014 26.867± 0.33 
CT8 0.375± 0.01 0.412± 0.011 8.9± 0.895 1.098± 0.011 27.839± 0.605 
CT9 0.346± 0.015 0.375± 0.013 7.583± 0.928 1.082± 0.011 26.338± 0.307 
CT10 0.396± 0.014 0.425± 0.011 6.988± 0.903 1.075± 0.01 25.249± 0.107 
CT11 0.38± 0.016 0.411± 0.015 7.634± 1.06 1.083± 0.012 26.916± 0.396 
CT12 0.382± 0.014 0.418± 0.012 8.544± 1.241 1.094± 0.015 26.648± 0.278 
 
* n=3; ** Calculated from average values of tapped density and bulk density. 
Table 6: Characterization of powder blends trial batch 
 
Formula final 
bulk density 
  
tapped density 
  
Compressibility 
index(%) 
  
Hausner’s 
Ratio 
  
Angle of repose  
(º) 
  
PG1 0.374 ± 0.001 0.462 ± 0.009 18.901 ± 1.759 1.234 ± 0.027 25.414 ± 0.549 
PG2 0.373 ± 0.004 0.457 ± 0.011 18.264 ± 2.746 1.225 ± 0.041 25.226 ± 0.835 
PG3 0.383 ± 0.004 0.456 ± 0.004 15.94 ± 1.528 1.19 ± 0.021 24.51 ± 0.439 
PG4 0.394 ± 0.005 0.462 ± 0.019 14.654 ± 4.183 1.174 ± 0.058 24.18 ± 1.197 
PG5 0.392 ± 0.002 0.469 ± 0.013 16.321 ± 2.709 1.196 ± 0.04 24.633 ± 0.814 
PG6 0.388 ± 0.004 0.459 ± 0.005 15.509 ± 1.495 1.184 ± 0.021 24.39 ± 0.437 
PG7 0.381 ± 0.004 0.463 ± 0.009 17.572 ± 1.305 1.214 ± 0.02 24.999 ± 0.404 
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PG8 0.394 ± 0.002 0.466 ± 0.002 15.514 ± 0.401 1.184 ± 0.006 24.38 ± 0.117 
PG9 0.397 ± 0.007 0.465 ± 0.004 14.756 ± 1.238 1.173 ± 0.017 24.168 ± 0.345 
* n=3; ** Calculated from average values of tapped density and bulk density 
 
Table 7: Post Compression parameters  of core tablet 
Hardness (kg/cm2) Friability (%) DT (sec) 
2.98 ± 0.13 0.82 ± 0.07 29 ± 1 
Table 8:Post Compression parameters of hydrogel plug 
Parameters Hardness friability 
PG1 3.87±0.06 0.767 ± 0.153 
PG2 4.13±0.06 0.6 ± 0.1 
PG3 4.37±0.06 0.467 ± 0.153 
PG4 2.47±0.4 0.567 ± 0.153 
PG5 2.87±0.06 0.633 ± 0.208 
PG6 3.17±0.06 0.6 ± 0.173 
PG7 3.57±0.29 0.333 ± 0.208 
PG8 3.9±0.17 0.733 ± 0.058 
PG9 4.07±0.12 0.567 ± 0.153 
 
Table 9:Lag time of Experimental batch 
Formulation code 
Immediate 
release tablet 
(mg) 
Hydrogel composition (mg) 
Lag 
Time(min) 
HPMC 
K15M 
Guar gum 
Avicel 
pH101 
Magnesium 
stearate 
 
PP1 150 45 30 24 1 410 
PP2 150 40 25 34 1 370 
PP3 150 45 25 29 1 400 
PP4 150 35 25 39 1 300 
PP5 150 35 30 34 1 320 
PP6 150 45 35 19 1 440 
PP7 150 40 35 24 1 390 
PP8 150 35 35 29 1 330 
PP9 150 40 30 29 1 380 
 
* n=3 
Table 10:ANOVA results of the model 
Std. Dev. Mean R-Squared 
Adj R-
Squared C.V. % PRESS 
Pred R-
Squared 
Adeq 
Precision 
7.1362403
21 
371.11111
11 
0.9909539
47 0.975877193 
1.9229390
09 
1849.3622
45 0.890498288 22.31102459 
SS- sum of squares, DF- degree of freedom, MS- Mean square, SD- Standard deviation 
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Figure 1: FTIR of drug with HPMC K15M 
 
Asian Pac. J. Health Sci., 2019; 6(1):10-21                                                  e-ISSN: 2349-0659, p-ISSN: 2350-0964 
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Abhimanyu et al                     ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2019;6(1):10-21                                  18 
www.apjhs.com       
 
 
Figure 2: FTIR of drug with GUAR GUM 
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Figure 3: In-vitro release profile of pulsed capsule PG1-PG9 
 
 
Figure 4: In-vitro release profile of pulsed capsule PP1-PP9 
 
 
 
Figure 5:Contour plot showing the influence of X1 and X2 on the lag time of pulsatile capsules of Valsartan 
0
20
40
60
80
100
120
0 100 200 300 400 500 600
C
u
m
u
la
ti
ve
%
 R
el
ea
se
Time(min)
PG1-PG9
PG1
PG2
PG3
PG4
PG5
PG6
PG7
PG8
PG9
0
100
200
0 50 100 150 200 250 300 350 400 450 500
C
u
m
u
la
ti
ve
 %
 
R
el
ea
se
Time(min)
PP1-PP9
PP1
PP2
PP3
PP4
PP5
Design-Expert® Softw are
lag time
Design Points
440
300
X1 = A: HPMC K15M
X2 = B: GUARGUM
-1.00 -0.50 0.00 0.50 1.00
-1.00
-0.50
0.00
0.50
1.00
lag time
A: HPMC K15M
B: G
UA
RG
UM
326.389
348.056
369.722 391.389
413.056
 
Asian Pac. J. Health Sci., 2019; 6(1):10-21                                                  e-ISSN: 2349-0659, p-ISSN: 2350-0964 
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Abhimanyu et al                     ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2019;6(1):10-21                                  20 
www.apjhs.com       
 
 
Figure 6: Surface response graph showing the influence of X1 and X2 on the lag time of pulsatile capsules of 
Valsartan 
 
 
Accelerated stability studies 
Accelerated stability studies on the optimized 
promising formulation ofpulsincap (PCZ1) was carried 
out by storing the formulations (in amber colored 
rubber stoppered vials) at 40±20C and 75±5% RH for 6 
months. At regular intervals the formulation was 
characterized for different parameters. It is shown that 
there was no change in physical appearance, weight, 
hardness, drug content during the study period and at 
the end of the six months. Also, no significant change 
was shown in the percent drug release, before and after 
storage. Thus, results imply good stability of the 
formulation on six-month storage.  Since the 
accelerated data showed little or no change over time 
and little variability, a statistical analysis was 
considered unnecessary. 
 
Conclusion 
It was concluded that, implementation of a suitable 
experimental design results in achievement of an 
appropriate formulation, in the shortest time with 
minimum efforts. Pulsincap formulation of valsartan 
prepared by using polymer HPMC and guar gum was 
found to be better alternative for the patients having 
rheumatoid arthritis that follows the circadian pattern 
because the prepared formulation released the drug 
according to the need of disease. Lag time for the 
release of drug from the optimized formulation was 
found to be 360 which was the desired value. Thus, it 
can be said that our prepared formulation might be 
beneficial in a diseased state to provide relief at its 
worst condition. 
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